Loading...
Market
Which clinical trial phase will Radionetics' leading radiopharmaceutical reach by end of 2025?
4
Resolution / Starting Odds
Phase 1 • 33%
Phase 2 • 33%
Phase 3 • 33%
Clinical trial registry and announcements from Radionetics Oncology
Story
Radionetics Oncology Enters $140M Strategic Agreement With Lilly, Acquisition Option for $1B
Jul 1, 2024, 02:51 PM
Radionetics Oncology has entered into a strategic agreement with Eli Lilly and Company. As part of the deal, Radionetics will receive a $140 million upfront payment. In return, Lilly gains the exclusive right to acquire Radionetics for $1 billion. The agreement focuses on enhancing Lilly's cancer drug pipeline with radiopharmaceuticals developed by Radionetics. Lilly inks the deal with the biotech startup to expand its radiopharmaceutical offerings.
View original story
Similar markets
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Phase 4 • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Approved • 25%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Not started • 25%
Trial halted • 25%
Limited efficacy • 25%
Moderate efficacy • 25%
High efficacy • 25%
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Not started • 25%
Preclinical • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 or beyond • 25%
